Navigation Links
Intrinsic Imaging Awarded Phase II Immuno-Oncology Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and Small Cell Lung Cancer
Date:3/22/2017

Intrinsic Imaging, LLC, an FDA audited and ISO certified medical imaging core lab with extensive therapeutic experience and operational excellence in oncology clinical trials, proudly announces today that it has been awarded a multi-year phase II immuno-oncology clinical trial for the treatment of non-small cell lung cancer and small cell lung cancer.

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including protocol and charter development, site qualification, site training and management, image transfer, quality control and processing. In addition, Intrinsic Imaging’s full-time board-certified, fellowship trained radiologists will also evaluate the patients’ tumor response according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criterion.

“Intrinsic Imaging was selected due to our extensive therapeutic experience and operational excellence in oncology and immuno-oncology clinical trials,” said Todd A. Joron, BSc., MBA, President & COO at Intrinsic Imaging. “With our team of 70 fellowship trained radiologists, robust and scalable clinical imaging technologies and our ISO certified quality management systems, Intrinsic Imaging is ideally positioned to provide our expertise in the assessment of non-small cell lung cancer and other lung cancers.”

Intrinsic Imaging's board-certified team includes 12 oncology focused radiologists with an extensive breadth of experience in clinical trials involving carcinomas, sarcomas, and lymphomas. The company also has significant expertise in a range of assessment criterion including , but not limited to, BIRADS, Cheson, irRECIST, Lugano, Macdonald, mRecist, PERCIST, RANO and RECIST.

Lung cancer is the leading cause of cancer death across the globe, claiming more lives than the next three most common cancers combined. Non-small cell lung cancer accounts for some 85% of lung cancer diagnoses. The five-year survival rate is low often due to most patients having advanced disease at the time of presentation. Intrinsic Imaging proudly lends its expertise on this clinical trial in an effort to help in the development of an effective treatment for lung cancer.

About Intrinsic Imaging, LLC
Located in Bolton, Massachusetts and San Antonio, Texas, Intrinsic Imaging is an FDA audited, ISO 9001, ISO 13485, ISO 22301 and ISO 27001 certified and GAMP5 compliant medical imaging core lab specializing in providing imaging core lab services for clinical trials. With its team of more than seventy full-time board-certified fellowship trained radiologists, robust and scalable clinical imaging technologies and its ISO certified quality management systems, Intrinsic Imaging is ideally positioned to provide unprecedented imaging core lab services around the world. For more information, please visit http://www.IntrinsicImaging.com

Read the full story at http://www.prweb.com/releases/2017/03/prweb14170750.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Intrinsic Clinical Systems Unveils a New Kind of Clinical Trial Management System
2. New Intrinsically Safe XPP-5454GC LED Headlamp from Nightstick® Now Clips Direct to Hard Hats
3. Dual Magnets Add Convenience to Safety in New Nightstick® XPP-5422GM Intrinsically Safe Dual-LightTM Flashlight
4. Intrinsic Imaging Awarded Medical Device Trial for Percutaneous Tumor Ablation
5. RSNA: Noninvasive Imaging Helps Predict Heart Attacks
6. Functional Imaging Supports Improved Cognition in Parkinson’s Disease Patients After REHACOP
7. Canopy Partners Launches Canopy CARE – An End-To-End Referral Management Platform For Medical Imaging Providers
8. Scottsdale Medical Imaging Recognized with Award from the Southwest Alliance for Excellence.
9. Camellia Women’s Imaging Helping Diminish Breast Cancer Screening Anxiety
10. RSNA: Imaging Links Structural Brain Changes and Cognitive Decline in Parkinson’s
11. NIH Awards Nocturnal Product Development and GW a $2.27M Phase II STTR Grant for Preclinical Development of Cardiac Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
(Date:9/18/2017)... Mich. , Sept. 18, 2017  PMD Healthcare ... Specialty Pharmacy of Kalamazoo, Mich. , ... hub service that expedites and streamlines patient and provider ... PD 2.0, and wellness management services.  ... device used to measure lung function for a variety ...
(Date:9/13/2017)... 2017   OrthoAtlanta has been named the official ... Committee (AFHC) for the 2018 College Football Playoff (CFP) National ... Mercedes-Benz Stadium in Atlanta, Georgia . OrthoAtlanta ... In" campaign, participating in many activities leading up to, and ... ...
Breaking Medicine Technology: